Who is eligible for clinical trial NCT06140836?

Participants must meet the protocol's inclusion criteria for Carcinoma, Non-Small-Cell Lung. The stated age range is 18 Years. Confirm all requirements with the study coordinator.

Does clinical trial NCT06140836 provide travel or cost reimbursement?

Check with the site coordinator at the participating facility for travel and lodging stipend availability, and for which routine-care costs are covered.

🏛️ Verified NIH Record • Updated 2025-11-18

A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3) (NCT06140836)

Randomized, Open-label, Multicenter, Phase 3 Trial of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-naïve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)

🔵 Active, Not Recruiting Phase3 💊 Investigational Drug / Biologic Sponsor: Bristol-Myers Squibb

🩺 Plain-English Summary (8th-Grade Level)

The purpose of this study is to evaluate the efficacy and safety of repotrectinib and crizotinib in participants with locally advanced or metastatic TKI-naïve ROS1-positive non-small cell lung cancer (NSCLC).

Who can join: To join this study, participants generally need to meet the listed inclusion criteria (6 items) and avoid the listed exclusions (5 items).

Location: Local Institution - 0221 — Des Moines, Iowa

Age range: 18 Years

🧪 Interventions in This Study

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Check every box below. If you can check all of them, you may meet the study's basic screening requirements (final eligibility is confirmed by the site team).

Participant has histologically or cytologically confirmed diagnosis of locally advanced or metastatic NSCLC
Participant has a ROS1 gene rearrangement/fusion as detected by a local test.
At least 1 measurable lesion according to RECIST v1.1, as assessed by the investigator.
Participants must not be exposed previously with TKIs that demonstrated activities in ROS1-positive NSCLC
Up to 1 prior line of systemic treatment for NSCLC is permitted
ECOG Performance Status ≤ 2

Usually NOT eligible if any of the following apply:

Exclusion Criteria:
Symptomatic brain metastases or symptomatic leptomeningeal involvement.
History of previous cancer requiring therapy within the previous 2 years, except for NSCLC under study, squamous cell or basal-cell carcinoma of the skin, or any in situ carcinoma that has been completely resected.
Known tumor targetable co-mutations or rearrangements
Clinically significant cardiovascular disease (either active or within 6 months prior to enrollment) Note: Other protocol-defined inclusion/exclusion criteria apply

🔍 Extracted verbatim from the official NIH eligibility criteria. Always confirm with the study coordinator.

📍 All Participating Trial Locations (122 Sites)

Showing the first 25 of 122 sites.

Local Institution - 0221 — Des Moines, Iowa
Local Institution - 0075 — Boston, Massachusetts
Local Institution - 0201 — Boston, Massachusetts
Local Institution - 0210 — Mineola, New York
Local Institution - 0134 — New York, New York
Local Institution - 0214 — Tacoma, Washington
Local Institution - 0092 — Ciudad Autónoma de Buenos Aires, Buenos Aires
Instituto Alexander Fleming — Ciudad Autónoma de Buenos Aires, Buenos Aires
Local Institution - 0091 — ABB, Buenos Aires F.D.
Local Institution - 0106 — Buenos Aires,
Local Institution - 0207 — Buenos Aires,
Local Institution - 0093 — Córdoba,
Local Institution - 0041 — Vienna,
Local Institution - 0073 — Belo Horizonte, Minas Gerais
Local Institution - 0033 — Porto Alegre, Rio Grande do Sul
Local Institution - 0034 — Porto Alegre, Rio Grande do Sul
Local Institution - 0029 — Barretos, São Paulo
Local Institution - 0037 — São José do Rio Preto, São Paulo
Local Institution - 0209 — São Paulo, São Paulo
Local Institution - 0147 — São Paulo, São Paulo
Local Institution - 0098 — Rio de Janeiro,
Local Institution - 0108 — Rio de Janeiro,
Local Institution - 0032 — São Paulo,
Local Institution - 0114 — São Paulo,
Local Institution - 0002 — Toronto, Ontario

💰 Cost, Insurance & Patient Rights

100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Carcinoma, Non-Small-Cell Lung

MYLUNG Consortium Study Protocol 2 — Daphne, Alabama
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009) — Gilbert, Arizona
THIO Sequenced With Cemiplimab in Advanced NSCLC — Birmingham, Alabama
A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions — Duarte, California
Oleclumab (MEDI9447) Epidermal Growth Factor Receptor Mutant (EGFRm) Non-small Cell Lung Cancer (NSCLC) Novel Combination Study — La Jolla, California

Explore by condition: All Carcinoma, Non-Small-Cell Lung clinical trials

💡 How to Participate

Check the checklist above to see if you may qualify.
Review the official NIH record below to find the coordinating site.
Ask about the visit schedule, what is covered at no cost, and any travel support.
Confirm with your own doctor before making a decision.

🏛️ View Official NIH Record ↗